Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer (NCT03036098)
A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating participants with previously untreated inoperable or metastatic urothelial cancer.
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0001 — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (174 Sites)
Showing the first 25 of 174 sites.
- Local Institution - 0001 — Anchorage, Alaska
- Local Institution - 0115 — Fresno, California
- St Joseph Heritage Healthcare — Santa Rosa, California
- Local Institution - 0051 — Boca Raton, Florida
- Local Institution - 0087 — Fort Lauderdale, Florida
- Local Institution - 0062 — Jacksonville, Florida
- Local Institution - 0004 — Athens, Georgia
- Local Institution - 0033 — Thomasville, Georgia
- Local Institution - 0046 — Chicago, Illinois
- Local Institution - 0117 — New Orleans, Louisiana
- Local Institution - 0056 — Boston, Massachusetts
- Local Institution - 0073 — Boston, Massachusetts
- Local Institution - 0208 — Boston, Massachusetts
- Local Institution - 0207 — Milford, Massachusetts
- Local Institution - 0063 — Ann Arbor, Michigan
- Local Institution - 0002 — Burnsville, Minnesota
- Hattiesburg Clinic — Hattiesburg, Mississippi
- Local Institution - 0032 — Kansas City, Missouri
- Local Institution - 0095 — St Louis, Missouri
- Local Institution - 0057 — Manchester, New Hampshire
- Local Institution - 0084 — Albuquerque, New Mexico
- Local Institution - 0083 — Buffalo, New York
- Local Institution - 0014 — Mineola, New York
- Local Institution - 0072 — New York, New York
- Local Institution - 0116 — Durham, North Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Urothelial Cancer
- Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer — Chandler, Arizona
- A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations — Anchorage, Alaska
- A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer — Cleveland, Ohio
- A Genotype-Phenotype Urothelial Cancer Registry — Basking Ridge, New Jersey
- Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies — Bethesda, Maryland
- Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer — Los Angeles, California
Explore by condition: All Urothelial Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.